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Abstract Panitumumab is a fully human monoclonal anti-
body that targets the epidermal growth factor receptor. Re-
sults from the primary analysis of a phase 3, randomized,
controlled study showed a statistically significant improve-
ment in progression-free survival for patients receiving
panitumumab; however, overall survival was confounded
by best supportive care (BSC) patients that crossed over to
panitumumab therapy after disease progression. Three post
hoc analyses are presented that approximate the
panitumumab overall survival treatment effect in both the
all-randomized and wild-type (WT) KRAS populations by
using the BSC patients with mutant (MT) KRAS as the
comparator group to discount the effect of crossover from
BSC to panitumumab. The primary post hoc analysis
showed a median overall survival of 6.4 months for all
KRAS-evaluable patients randomized to panitumumab ver-
sus 4.4 months for patients with MT KRAS tumors random-
ized to BSC, yielding an adjusted hazard ratio (95 % CI) of
0.764 (0.598-0.977). Similar results were observed for the
two secondary post hoc analyses. These analyses suggest a
positive treatment effect of panitumumab in both the overall
and WT KRAS patient populations consistent with an im-
provement in overall survival relative to BSC.
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Introduction
Colorectal cancer is the third most common cancer in the
world, with more than 1.2 million new cases diagnosed annu-
ally [1]. Treatment options for metastatic colorectal cancer
(mCRC) include monoclonal antibodies that target the epider-
mal growth factor receptor (EGFR) [2–7]. Panitumumab
(Vectibix®, [Amgen Inc., Thousand Oaks, United States]), a
fully human monoclonal antibody that targets the EGFR, is
approved in the US as monotherapy for mCRC after disease
progression, in the European Union for the treatment of pa-
tients with wild-type (WT) KRAS mCRC in first-line in com-
bination with FOLFOX (leucovorin, fluorouracil, and
oxaliplatin), in second-line in combination with FOLFIRI
(leucovorin, fluorouracil, and irinotecan) in patients who have
received first-line fluoropyrimidine-based chemotherapy
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Fig. 1 a 20020408 Study Schema, b CONSORT diagram, c groups
included in the primary post hoc analysis that compared patients with
MT KRAS (n=84) and WT KRAS (n=124) tumors who received
panitumumab versus patients with MT KRAS (n=100) tumors who
received BSC alone. d Groups included in the second post hoc analysis
that compared patients with WT KRAS (n=124) tumors who received
panitumumab versus patients with MT KRAS (n=100) tumors who
received BSC alone. e Groups included in the third post hoc analysis
that compared patients with WT KRAS tumors who received
panitumumab (n=124) and BSC alone (n=119) versus patients with
MT KRAS tumors who received panitumumab (n=84) and BSC alone
(n=100)
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(excluding irinotecan), and in third-line as monotherapy, and
in Canada as monotherapy for the treatment of patients with
EGFR-expressing WT KRAS mCRC after failure of
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing
chemotherapy regimens.
During the conduct of a phase 3 trial (the 20020408 study)
that prospectively compared panitumumab plus best supportive
care (BSC) to BSC alone in patients with mCRC, a strong
correlation emerged with a lack of EGFR inhibitor activity in
patients with mutant (MT) KRAS tumors [8]. The primary
endpoint of this study was progression-free survival (PFS).
Patients randomized to BSC could cross over to panitumumab
therapy in the event of disease progression on-study. Results
from the primary analysis showed a statistically significant
improvement in PFS for patients receiving panitumumab;
however, the overall survival (OS) hazard ratio (HR) for
panitumumab versus BSC was 1.00, a result confounded by
the 176 (76 %) BSC patients that crossed over to
panitumumab therapy after disease progression; crossover
occurred early, with a median time to crossover of 7 weeks
(range, 6.6 to 7.3 weeks) [2].
Patients with MT KRAS tumors do not benefit from anti-
EGFR therapy, a finding confirmed in other studies and meta-
analyses of EGFR inhibitors [9–13]. In theMTKRAS group in
our study, no OS difference was observed between treatment
arms, as evidenced by an HR (95 % CI) of 1.02 (0.75 to 1.39)
[8]. In other studies,KRAS status was not prognostic for OS in
patients that received BSC, chemotherapy, and chemotherapy
with bevacizumab [4, 14–19]. Two meta-analyses examining
tumor KRAS status and anti-EGFR monoclonal antibodies in
mCRC show MT KRAS mCRC is associated with reduced
overall and progression-free survival [12, 13]. Therefore, pa-
tients with MT KRAS receiving BSC with disease progression
that went on to receive panitumumab likely did not benefit
from panitumumab therapy. For this reason, using the MT
KRAS BSC group as the comparator may remove
confounding from crossover as opposed to using the entire
BSC alone group, which includes patients withWTKRAS that
benefited from panitumumab.
This paper describes the results from three post hoc analy-
ses of the 20020408 study that present approximations of the
panitumumab OS treatment effect in both the all-randomized
(ITT) and KRAS WT populations when crossover from BSC
to panitumumab is discounted by using the BSC patients with
MT KRAS as the comparator group.
Patients and methods
Patients
The patients and methods for this study were previously
described [2]. Briefly, eligible patients had documented
disease progression after failure of fluoropyrimidines,
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Table 1 Demographics and disease characteristics




Tertiary analysis Tertiary analysis
WT and MT KRAS
panitumumab








n=208 n=100 n=124 n=243 n=184
Sex, n (%)
Male 130 (63) 64 (64) 83 (67) 159 (65) 111 (60)
Age, years
Median (min, max) 62.0 (27, 82) 62.0 (27, 83) 62.5 (29, 82) 63.0 (29, 82) 62.0 (27, 83)
Race, n (%)
White 206 (99) 97 (97) 122 (98) 240 (99) 181 (98)
ECOG, n (%)
0 96 (46) 37 (37) 53 (43) 93 (38) 80 (43)
1 84 (40) 47 (47) 56 (45) 118 (49) 75 (41)
2 28 (13) 15 (15) 15 (12) 31 (13) 28 (15)
3 0 (0) 1 (1) 0 (0) 1 (<1) 1 (<1)
Primary tumor type, n (%)
Colon 139 (67) 65 (65) 86 (69) 168 (69) 118 (64)
Rectal 69 (33) 35 (35) 38 (31) 75 (31) 66 (36)
Number of sites of disease
1 58 (28) 20 (20) 38 (31) 68 (28) 40 (22)
2 84 (40) 49 (49) 50 (40) 104 (43) 83 (45)
3 42 (20) 25 (25) 21 (17) 43 (18) 46 (25)
4 22 (11) 2 (2) 14 (11) 24 (10) 10 (5)
5 2 (1) 4 (4) 1 (1) 2 (1) 5 (3)
Sites of disease
Liver 161 (77) 81 (81) 96 (77) 199 (82) 146 (79)
Lung 128 (62) 64 (64) 69 (56) 138 (57) 124 (67)
Lymph nodes 47 (23) 24 (24) 31 (25) 67 (28) 40 (22)
Abdomen 35 (17) 20 (20) 23 (19) 40 (16) 32 (17)
Pelvic site 22 (11) 9 (9) 11 (9) 18 (7) 20 (11)
Bone 14 (7) 3 (3) 9 (7) 15 (6) 8 (4)
Chest 9 (4) 4 (4) 6 (5) 8 (3) 7 (4)
Gastrointestinal 8 (4) 3 (3) 5 (4) 8 (3) 6 (3)
Skin 3 (1) 1 (1) 1 (1) 2 (1) 3 (2)
Spleen 2 (1) 1 (1) 1 (1) 2 (1) 2 (1)
Central nervous system 1 (<1) 0 (0) 1 (1) 1 (<1) 0 (0)
Head 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Neck 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other 19 (9) 11 (11) 9 (7) 13 (5) 21 (11)
Any prior chemotherapya 208 (100) 100 (100) 124 (100) 243 (100) 184 (100)
Prior adjuvant chemotherapy 77 (63) 40 (40) 50 (40) 82 (34) 67 (36)
Prior anti-tumor therapyb 12 (6) 2 (2) 7 (6) 12 (5) 7 (4)
Prior radiotherapy (includes
radiofrequency ablation)
54 (26) 29 (29) 29 (23) 62 (26) 54 (29)
Last regimen prior to study entry
Oxaliplatin containing regimens 88 (42)) 43 (43) 57 (46) 106 (44) 74 (40)
Irinotecan containing regimens 97 (47) 50 (50) 55 (44) 110 (45) 92 (50)
Both oxaliplatin and irinotecan 1 (<1) 0 (0) 1 (1) 3(1) 0(0)
19 (9) 6 (6) 10 (8) 21 (9) 15 (8)
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Cooperative Oncology Group (ECOG) performance status
0-2, no brain metastases, no systemic chemotherapy, or
radiotherapy within 30 days before randomization, and no
prior anti-EGFR therapy.
Study design and treatment schedule
This was an open-label, multicenter, phase 3 trial. Patients
were randomized 1:1 to receive panitumumab plus BSC or
BSC alone, and randomization was stratified by geographic
region (Western Europe versus Central and Eastern Europe
versus rest of the world [Canada, Australia, and New
Zealand]), and ECOG performance status score (0 or 1
versus 2). Panitumumab was administered intravenously
over 1 h at 6.0 mg/kg every 2 weeks (Q2W). Treatment
was administered until disease progression or unacceptable
toxicity (Fig. 1a).
As mentioned previously, BSC patients could receive
panitumumab after investigator-assessed disease progression.
The protocol was approved by the ethics committee at
participating sites, and all patients signed informed consent
before any study-related procedures were performed.
Statistical analyses
At the time the study was designed, the impact of tumor
KRAS status on the efficacy of anti-EGFR antibodies was
unknown; therefore, these analyses were not pre-specified in
the original statistical analysis plan. The emergence of WT
KRAS status as a requirement for panitumumab efficacy led
to the subgroup analyses described here.
The primary objective of these post hoc analyses was to
evaluate the OS treatment effect in both the ITT and WT
KRAS populations after discounting the effect of crossover
from the BSC group to panitumumab after disease progres-
sion. These exploratory and descriptive analyses included
only patients with known KRAS status; all subgroups were
defined prior to conducting any of the analyses.
The primary post hoc analysis was designed to best
emulate what would have been expected in the original trial
had there been no crossover from the BSC group to
panitumumab; as such, this analysis included all KRAS-
evaluable patients (both WT and MT) randomized to
panitumumab versus patients with MT KRAS tumors ran-
domized to BSC.
The second post hoc analysis was similar to the primary
post hoc analysis but excluded patients randomized to
panitumumab with MT KRAS tumors. In this analysis, pa-
tients randomized to panitumumab with WT KRAS tumors
were compared with patients in the BSC group with MT
KRAS tumors. Since patients with MT KRAS tumors were
unlikely to benefit from panitumumab, this analysis provid-
ed an estimate of the treatment effect of panitumumab in
patients with WT KRAS tumors.
The third post hoc analysis included all KRAS-evaluable
patients with WT KRAS mCRC versus all patients with MT
KRAS mCRC, regardless of the therapy to which each
patient was randomized. The WT KRAS group included
patients that received panitumumab and BSC alone, includ-
ing patients who received panitumumab after failure of BSC
treatment, potentially underestimating the panitumumab
treatment effect. Similarly, the MT KRAS group included
Table 1 (continued)




Tertiary analysis Tertiary analysis
WT and MT KRAS
panitumumab








n=208 n=100 n=124 n=243 n=184
Fluoropyrimidine without
oxaliplatin or irinotecan
Other 0 (0) 1 (1) 1 (1) 3(1) 3 (2)
Region, n (%)
Western Europe 157 (75) 77 (77) 93 (75) 187 (77) 141 (77)
Central/Eastern Europe 19 (9) 7 (7) 9 (7) 19 (8) 17 (9)
Rest of world 32 (15) 16 (16) 22 (18) 37 (15) 26 (14)
EQ-5D score at baseline, median
(min, max)c
0.76 (0.16, 1.00) 0.73 (0.59, 1.00) 0.76 (0.16,
1.00)
0.74 (0.16, 1.00) 0.73 (0.59, 1.00)
FACT-CRC raw score at
baseline, mean (SD)
77.8 (15.3) 77.4 (16.6) 78.8 (14.7) 78.9 (14.3) 76.9 (16.3)
a Patients had multiple prior regimens
b Does not include systemic chemotherapy; does include carboplatin as chemo-embolization
c EQ-5D score range, 0.0 (death) to 1.0 (perfect health)
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patients that received panitumumab and BSC alone, includ-
ing patients who received panitumumab after failure of BSC
treatment. Neither of these MT KRAS groups was likely to
benefit from panitumumab.
For all of the post hoc analyses, Kaplan-Meier curves to
estimate the OS difference between groups were generated.
Crude and adjusted HRs for OS were estimated using Cox
proportional hazards models. The crude models included
only the geographic region and ECOG performance status
score stratification factors. Adjusted models included vari-
ables potentially associated with OS, namely age, sex, tumor
site, and baseline ECOG performance status score. Since
these analyses were post hoc with the objective to approx-
imate the OS treatment effect, no pvalues were calculated,
and no assessment of statistical significance was made. All
analyses were conducted with SAS software version 9.2
(SAS Institute, Cary, NC).
Sensitivity analyses
A key assumption for these post hoc analyses is a lack of
prognostic value of KRAS status in patients treated with
BSC alone. Although this assumption is supported by the
literature, an analysis to examine the OS treatment effect in
patients randomized to BSC alone that did not cross over to
panitumumab by KRAS status was performed [8, 11]. This
subgroup, however, may not be representative of the overall
BSC alone population, since the primary reason for lack of
crossover was early death.
Results
From January 2004 to June 2005, 463 patients were enrolled
and randomized, 231 to panitumumab plus BSC versus 232
to BSC-alone. KRAS results were available for 427 (92 %)
patients, 208 panitumumab plus BSC and 219 BSC alone
(Fig. 1b). Of the 219 BSC-alone patients with known KRAS,
168 (77 %) crossed over to receive panitumumab at a
median time of 7.1 weeks.
For these post hoc analyses, different treatment groups
were utilized: patients with WT and MT KRAS receiving
panitumumab (n=208), patients with WT KRAS enrolled in
the panitumumab arm (n=124), patients with MT KRAS
enrolled in the BSC arm (n=100), patients with WT KRAS
receiving panitumumab and BSC (n=243), and patients
with MT KRAS receiving panitumumab and BSC (n=184)
(Fig. 1c–e). Baseline demographics, disease characteristics,
and quality-of-life measures were similar among all com-
parator groups (Table 1).
The primary analysis results indicate median OS was
6.4 months for all KRAS-evaluable patients randomized to
HR (95% CI) = 0.764 (0.598 – 0.977)
Fig. 2 Kaplan–Meier estimate
of overall survival for KRAS-
evaluable patients randomized
to panitumumab versus patients
randomized to BSC with KRAS
mutant tumors
Table 2 Summary of OS HR estimates from the post hoc analyses
Description Crude HR (95 % CI) Adjusted HRa (95 % CI) Median (months)
WT and MT KRAS panitumumab versus MT KRAS BSC 0.777 (0.606–0.996) 0.764 (0.598–0.977) 6.4 vs 4.4
WT KRAS panitumumab versus MT KRAS BSC 0.668 (0.505–0.883) 0.656 (0.494–0.872) 8.1 vs 4.4
WT KRAS panitumumab+BSC versus MT KRAS panitumumab+BSC 0.668 (0.546–0.818) 0.622 (0.506–0.764) 7.9 vs 4.7
a HR adjusted for variables potentially associated with OS: age, sex, tumor site, and baseline ECOG score
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panitumumab versus 4.4 months for patients with MT KRAS
tumors randomized to BSC (Fig. 2). Table 2 presents the
crude and adjusted HRs for the post hoc analyses. This
approximation of the all-randomized panitumumab OS
treatment effect yielded an adjusted HR (95 % CI) of
0.764 (0.598-0.977).
In the second analysis, median OS was 8.1 months for
pat ients wi th WT KRAS tumors randomized to
panitumumab versus 4.4 months for patients with MT KRAS
tumors randomized to BSC (Fig. 3). This approximation of
the WT KRAS panitumumab OS treatment effect yielded an
adjusted HR (95 % CI) of 0.656 (0.494-0.872; Table 2).
In the third analysis, median OS was 7.9 months for all
patients with WT KRAS versus 4.7 months for all patients
with MT KRAS tumors, regardless of treatment group as-
signment (Fig. 4). This approximation of the WT KRAS
panitumumab OS treatment effect yielded an adjusted HR
(95 % CI) of 0.622 (0.506-0.764; Table 2).
The post hoc analyses presented above depend on the
assumption that KRAS status has no prognostic effect on OS
in patients treated with BSC alone. As such, a sensitivity
analysis of patients randomized to BSC that did not cross
over to panitumumab by tumor KRAS status was performed
that found median OS was 1.9 months for patients (n=28)
with WT KRAS tumors and 2.0 months for patients (n=23)
with MT KRAS tumors (Fig. 5). Although this subgroup
may not be representative of the overall BSC population,
these results support the assumption that tumor KRAS status
has no prognostic impact on patients treated with BSC
alone, upholding this post hoc analysis.
An additional sensitivity analysis was performed since
patients were not randomized at the level of KRAS status. It
is possible that imbalances in unmeasured prognostic factors
(other than those considered in the adjusted model) may
have introduced residual confounding. Thus, a sensitivity
analysis using the array approach was conducted to quantify
HR (95% CI) = 0.656 (0.494 – 0.872)
Fig. 3 Kaplan–Meier estimate
of overall survival for patients
randomized to panitumumab
with KRAS wild-type tumors
versus patients randomized to
BSC patients with KRAS
mutant tumor
HR (95% CI) = 0.622 (0.506 – 0.764)
Fig. 4 Kaplan–Meier estimate
of overall survival for patients
with KRAS wild-type versus
KRAS mutant tumors
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the effect of a known or unknown, unmeasured confounder
on the observed association between panitumumab and OS
in the ITT population [20].
Using this approach, we fixed the prevalence of a hypo-
thetical confounder in the BSC MT KRAS group to 0.3 and
varied the strength of the confounder–outcome association
(1.0 to 5.5) and the prevalence of the confounder in the
panitumumab group (0.0 to 5.0). The interrelationship be-
tween these three factors was plotted in three-dimensional
graphic representation (Fig. 6).
There is no bias when the confounder is equally distrib-
uted between the panitumumab and BSC MT KRAS tumor
groups. However, with increasing imbalance of the con-
founder between the two groups, the fully adjusted estimate
moves away from the observed HR. Specifically, if the
prevalence of the confounder in the panitumumab group is
inferior to the prevalence of the confounder in the BSC MT
KRAS tumor group, then the “true” HR would be higher
than the observed HR. This would require the confounder to
be strongly associated with the outcome, with RR estimates
ranging from 3.5 to 5.5. Conversely, if the prevalence of the
confounder in the panitumumab group is superior to the
prevalence of the confounder in the BSC MT KRAS tumor
group, then the “true” HR would be less than the observed
HR. Other than age, sex, tumor site, and ECOG perfor-
mance status score, all of which were controlled for in the
adjusted model, the likelihood of an unknown, unmeasured
confounder of a magnitude necessary to impact outcomes is
slim.
This sensitivity analysis demonstrates through quantifica-
tion of the effect of a known or unknown, unmeasured con-
founder on the observed association between panitumumab
Events / N (%)
 Median
in Months
BSC - wild-type 25 / 28  ( 89 ) 1.9

























28 11 5 4 2 2 1 1 1 1 1 1
23 11 3 1 1 0 0 0 0 0 0 0
Fig. 5 Kaplan–Meier estimate
of overall survival by KRAS
status among BSC patients that
did not crossover to
panitumumab
Fig. 6 Array approach for
confounding bias
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and OS that, if these post hoc analyses are subject to bias, that
either a confounder with an unlikely magnitude of impact
exists or the observed OS effect is valid in spite of the bias.
Discussion
The results from these analyses suggest that crossover from
BSC to panitumumab had an impact on OS in both the
overall and WT KRAS patient populations. Controlling for
these crossover patients demonstrated a trend toward im-
proved OS that could have been detected in the original
study if crossover were not permitted. Since patients with
MT KRAS tumors were unlikely to benefit from
panitumumab therapy and the evidence suggests KRAS has
no OS prognostic effect with BSC alone, this post hoc
analysis gives an approximation of the all-randomized treat-
ment effect of panitumumab on OS after discounting the
impact of crossover from BSC to panitumumab treatment in
the original trial. In a similar manner, the second and third
analyses provided approximations of the treatment effect of
panitumumab on OS in patients with WT KRAS tumors, also
discounting the effect of crossover. In these analyses, the
HRs were consistently under 1, suggesting a positive
panitumumab treatment effect. Of note, a similar improve-
ment in OS was observed with cetuximab therapy relative to
BSC alone in a trial in which no crossover was allowed in a
similar patient population [4]. The results of these post hoc
analyses are consistent with the statistically significant PFS
effect from the primary analysis of this study.
Post hoc analyses and the conclusions that can be
drawn from them are limited by bias. Concerns included
the introduction of bias through patient selection, whether
tumor KRAS status was prognostic for OS with BSC
alone, and the treatment effect of panitumumab, if any,
on OS in patients with MT KRAS tumors. Patient selec-
tion bias was minimized because the demographics and
disease characteristics of the control groups represented a
random sample of patients enrolled in the study. Indeed,
the demographics and disease characteristics of the con-
trol groups were similar to all other comparator groups in
these analyses. The assumption that tumor KRAS status is
not prognostic for OS is supported in both the literature
and in the trend toward no difference between patients
with WT and MT KRAS tumors in patients randomized
to BSC that did not cross over to panitumumab. In
addition, patient treatment decisions were made without
knowledge of tumor KRAS status. Evidence for the lack
of a treatment effect of panitumumab on OS in patients
with MT KRAS tumors from the original KRAS analysis
of this study provided further evidence of the lack of
bias that might be introduced by using patients with MT
KRAS tumors as a comparator group.
The crude and adjusted HR estimates in the three
analyses were very similar, indicating that the potential
confounders considered were relatively well-balanced
between the exposure groups. Furthermore, the sensitiv-
ity analysis based on the array approach indicated that it
is unlikely that the observed results were biased by an
unknown or unmeasured confounder [20]. In fact,
confounding bias would only be present in extreme
conditions, with a confounder very strongly associated
with the outcome being largely differentially distributed
between the exposure groups. Such a scenario is
thought to be unlikely, as we adjusted for known im-
portant confounders.
In summary, these analyses show a positive treatment
effect of panitumumab on OS in both the overall and WT
KRAS patient populations that could have been detected in
the original study and in the prospective–retrospective anal-
ysis by KRAS status if crossover from BSC to panitumumab
had not been permitted.
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